{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:28:08Z","timestamp":1786350488051,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08118-4","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:34:04Z","timestamp":1786347244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing hematological toxicity in [\u00b9\u2077\u2077Lu]Lu-DOTATATE for NET patients: a national survey from the French group of endocrine tumors (GTE) on the clinical need for harmonized monitoring strategies"],"prefix":"10.1007","author":[{"given":"S.","family":"Oziel-Taieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ansquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tlili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-7602","authenticated-orcid":false,"given":"M.","family":"Haissaguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"2","key":"8118_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"10446","key":"8118_CR2","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for newly diagnosed advanced grade 2\u20133 gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"issue":"4","key":"8118_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2967\/jnumed.122.264422","volume":"64","author":"E Hindi\u00e9","year":"2023","unstructured":"Hindi\u00e9 E, Baudin E, Hicks RJ, Ta\u00efeb D. The latest advances in peptide receptor radionuclide therapy for gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2023;64(4):522\u20134. https:\/\/doi.org\/10.2967\/jnumed.122.264422.","journal-title":"J Nucl Med"},{"issue":"16","key":"8118_CR4","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8118_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, Kam BLR, Teunissen JJM, Kooij PP, de Herder WW, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43(3):453\u201363. https:\/\/doi.org\/10.1007\/s00259-015-3193-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8118_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.117.189712","volume":"59","author":"H Bergsma","year":"2018","unstructured":"Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLR, Teunissen JJM, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018;59(3):452\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.189712.","journal-title":"J Nucl Med"},{"issue":"11","key":"8118_CR7","doi-asserted-by":"publisher","first-page":"e0260073","DOI":"10.1371\/journal.pone.0260073","volume":"16","author":"DMV De Vries-Huizing","year":"2021","unstructured":"De Vries-Huizing DMV, Versleijen MWJ, Sinaasappel M, Walraven I, Geluk-Jonker MM, Tesselaar MET, et al. Haematotoxicity during peptide receptor radionuclide therapy: baseline parameters differences and effect on patient\u2019s therapy course. PLoS ONE. 2021;16(11):e0260073. https:\/\/doi.org\/10.1371\/journal.pone.0260073.","journal-title":"PLoS ONE"},{"key":"8118_CR8","doi-asserted-by":"publisher","first-page":"1568243","DOI":"10.3389\/fendo.2025.1568243","volume":"16","author":"R Ferrara","year":"2025","unstructured":"Ferrara R, Zemmour C, Reichert T, Ouk D, Niccoli P, Maniry-Quellier J, et al. Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors. Front Endocrinol (Lausanne). 2025;16:1568243. https:\/\/doi.org\/10.3389\/fendo.2025.1568243.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"8118_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020;6(7):1086\u201392. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0078.","journal-title":"JAMA Oncol"},{"issue":"11","key":"8118_CR10","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/cncr.34191","volume":"128","author":"KR Kennedy","year":"2022","unstructured":"Kennedy KR, Turner JH, MacDonald WBG, Claringbold PG, Boardman G, Ransom DT. Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy. Cancer. 2022;128(11):2182\u201392. https:\/\/doi.org\/10.1002\/cncr.34191.","journal-title":"Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08118-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08118-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08118-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:34:05Z","timestamp":1786347245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08118-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":10,"alternative-id":["8118"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08118-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is based on an anonymous survey conducted among healthcare professionals and did not involve patient data.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Oziel-Taieb, C. Ansquer, G. Tlili, E. Deshayes and M. Haissaguerre report having received honoraria for educational activities and\/or advisory board participation from Novartis\/AAA outside the submitted work. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}